{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T21:29:27Z","timestamp":1790890167776,"version":"4.1.0"},"reference-count":68,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T00:00:00Z","timestamp":1743465600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T00:00:00Z","timestamp":1743465600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,1,11]],"date-time":"2025-01-11T00:00:00Z","timestamp":1736553600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["jthjournal.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Thrombosis and Haemostasis"],"published-print":{"date-parts":[[2025,4]]},"DOI":"10.1016\/j.jtha.2024.12.039","type":"journal-article","created":{"date-parts":[[2025,1,10]],"date-time":"2025-01-10T12:17:17Z","timestamp":1736511437000},"page":"1169-1184","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":6,"title":["Tolerance to factor VIII in the era of nonfactor therapies: immunologic perspectives and a systematic review of the literature"],"prefix":"10.1016","volume":"23","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8278-9428","authenticated-orcid":false,"given":"Lilianne Esm\u00e9e","family":"van Stam","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5625-8447","authenticated-orcid":false,"given":"S\u00e9bastien","family":"Lacroix-Desmazes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0904-4360","authenticated-orcid":false,"given":"Karin","family":"Fijnvandraat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1957-4122","authenticated-orcid":false,"given":"Samantha Claudia","family":"Gouw","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jtha.2024.12.039_bib1","doi-asserted-by":"crossref","first-page":"540","DOI":"10.7326\/M19-1208","article-title":"Establishing the prevalence and prevalence at birth of hemophilia in males: a meta-analytic approach using national registries","volume":"171","author":"Iorio","year":"2019","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.jtha.2024.12.039_bib2","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1186\/s12955-018-0908-9","article-title":"The impact of severe haemophilia and the presence of target joints on health-related quality-of-life","volume":"16","author":"O'Hara","year":"2018","journal-title":"Health Qual Life Outcomes"},{"key":"10.1016\/j.jtha.2024.12.039_bib3","first-page":"1368","article-title":"Mild and moderate hemophilia A: neglected conditions, still with unmet needs","volume":"12","author":"Castaman","year":"2023","journal-title":"J\u00a0Clin Med"},{"key":"10.1016\/j.jtha.2024.12.039_bib4","doi-asserted-by":"crossref","first-page":"560","DOI":"10.1055\/s-0037-1615621","article-title":"Definitions in hemophilia. Recommendation of the scientific subcommittee on factor VIII and factor IX of the scientific and standardization committee of the International Society on Thrombosis and Haemostasis","volume":"85","author":"White","year":"2001","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.jtha.2024.12.039_bib5","doi-asserted-by":"crossref","first-page":"e1","DOI":"10.1111\/j.1365-2516.2012.02909.x","article-title":"Guidelines for the management of hemophilia","volume":"19","author":"Srivastava","year":"2013","journal-title":"Haemophilia"},{"key":"10.1016\/j.jtha.2024.12.039_bib6","doi-asserted-by":"crossref","first-page":"700","DOI":"10.1016\/j.jtha.2022.11.020","article-title":"Different inhibitor incidence for individual factor VIII concentrates in 1076 previously untreated patients with severe hemophilia A: data from the PedNet cohort","volume":"21","author":"Fischer","year":"2023","journal-title":"J\u00a0Thromb Haemost"},{"key":"10.1016\/j.jtha.2024.12.039_bib7","doi-asserted-by":"crossref","first-page":"4046","DOI":"10.1182\/blood-2012-09-457036","article-title":"Intensity of factor VIII treatment and inhibitor development in children with severe hemophilia A: the RODIN study","volume":"121","author":"Gouw","year":"2013","journal-title":"Blood"},{"key":"10.1016\/j.jtha.2024.12.039_bib8","doi-asserted-by":"crossref","first-page":"1055","DOI":"10.1111\/jth.14124","article-title":"Factor VIII products and inhibitor development in previously treated patients with severe or moderately severe hemophilia A: a systematic review","volume":"16","author":"Hassan","year":"2018","journal-title":"J\u00a0Thromb Haemost"},{"key":"10.1016\/j.jtha.2024.12.039_bib9","doi-asserted-by":"crossref","first-page":"1954","DOI":"10.1182\/blood-2013-02-483263","article-title":"Factor VIII gene (F8) mutation and risk of inhibitor development in nonsevere hemophilia A","volume":"122","author":"Eckhardt","year":"2013","journal-title":"Blood"},{"key":"10.1016\/j.jtha.2024.12.039_bib10","doi-asserted-by":"crossref","first-page":"436","DOI":"10.1046\/j.1365-2516.2003.00781.x","article-title":"Immune tolerance induction in patients with haemophilia A with inhibitors: a systematic review","volume":"9","author":"Wight","year":"2003","journal-title":"Haemophilia"},{"key":"10.1016\/j.jtha.2024.12.039_bib11","doi-asserted-by":"crossref","DOI":"10.1177\/20406207231165857","article-title":"Considerations for shared decision management in previously untreated patients with hemophilia A or B","volume":"14","author":"Astermark","year":"2023","journal-title":"Ther Adv Hematol"},{"key":"10.1016\/j.jtha.2024.12.039_bib12","doi-asserted-by":"crossref","first-page":"889","DOI":"10.1111\/hae.14412","article-title":"Prophylaxis in children with haemophilia in an evolving treatment landscape","volume":"27","author":"Mancuso","year":"2021","journal-title":"Haemophilia"},{"issue":"Suppl 6","key":"10.1016\/j.jtha.2024.12.039_bib13","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1111\/hae.14046","article-title":"WFH Guidelines for the Management of Hemophilia panelists and co-authors. WFH Guidelines for the Management of Hemophilia, 3rd edition","volume":"26","author":"Srivastava","year":"2020","journal-title":"Haemophilia"},{"key":"10.1016\/j.jtha.2024.12.039_bib14","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1080\/17474086.2020.1739518","article-title":"Patients with hemophilia A and inhibitors: prevention and evolving treatment paradigms","volume":"13","author":"Lillicrap","year":"2020","journal-title":"Expert Rev Hematol"},{"key":"10.1016\/j.jtha.2024.12.039_bib15","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1002\/rth2.12475","article-title":"Emicizumab in tolerized patients with hemophilia A with inhibitors: A single-institution pediatric cohort assessing inhibitor status","volume":"5","author":"Batsuli","year":"2021","journal-title":"Res Pract Thromb Haemost"},{"key":"10.1016\/j.jtha.2024.12.039_bib16","doi-asserted-by":"crossref","first-page":"e551","DOI":"10.1111\/hae.14311","article-title":"Recurrence of a high-titre factor VIII inhibitor in a haemophilia A patient on emicizumab prophylaxis","volume":"27","author":"Doshi","year":"2021","journal-title":"Haemophilia"},{"key":"10.1016\/j.jtha.2024.12.039_bib17","doi-asserted-by":"crossref","first-page":"e581","DOI":"10.1111\/hae.14334","article-title":"Reappearance of inhibitor in a tolerized patient with severe haemophilia A during FVIII-free emicizumab therapy","volume":"27","author":"Capdevila","year":"2021","journal-title":"Haemophilia"},{"key":"10.1016\/j.jtha.2024.12.039_bib18","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1111\/j.1365-2516.2008.01880.x","article-title":"The North American Immune Tolerance Registry: contributions to the thirty-year experience with immune tolerance therapy","volume":"15","author":"Dimichele","year":"2009","journal-title":"Haemophilia"},{"key":"10.1016\/j.jtha.2024.12.039_bib19","first-page":"1186","article-title":"Immune tolerance in hemophilia with factor VIII inhibitors: predictors of success","volume":"86","author":"Mariani","year":"2001","journal-title":"Haematologica"},{"key":"10.1016\/j.jtha.2024.12.039_bib20","doi-asserted-by":"crossref","first-page":"1980","DOI":"10.1111\/jth.13143","article-title":"Inhibitor recurrence after immune tolerance induction: a multicenter retrospective cohort study","volume":"13","author":"Antun","year":"2015","journal-title":"J\u00a0Thromb Haemost"},{"key":"10.1016\/j.jtha.2024.12.039_bib21","doi-asserted-by":"crossref","first-page":"3795","DOI":"10.1073\/pnas.89.9.3795","article-title":"Natural antibodies to factor VIII (anti-hemophilic factor) in healthy individuals","volume":"89","author":"Algiman","year":"1992","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.jtha.2024.12.039_bib22","doi-asserted-by":"crossref","first-page":"1496","DOI":"10.1172\/JCI117489","article-title":"Healthy subjects produce both anti-factor VIII and specific anti-idiotypic antibodies","volume":"94","author":"Gilles","year":"1994","journal-title":"J\u00a0Clin Invest"},{"key":"10.1016\/j.jtha.2024.12.039_bib23","doi-asserted-by":"crossref","first-page":"1039","DOI":"10.1182\/blood-2012-07-444877","article-title":"Distinct characteristics of antibody responses against factor VIII in healthy individuals and in different cohorts of hemophilia A patients","volume":"121","author":"Whelan","year":"2013","journal-title":"Blood"},{"key":"10.1016\/j.jtha.2024.12.039_bib24","doi-asserted-by":"crossref","first-page":"2946","DOI":"10.1182\/blood.V79.11.2946.2946","article-title":"Origin of anti-idiotypic activity against anti-factor VIII autoantibodies in pools of normal human immunoglobulin G (IVIg)","volume":"79","author":"Dietrich","year":"1992","journal-title":"Blood"},{"key":"10.1016\/j.jtha.2024.12.039_bib25","doi-asserted-by":"crossref","first-page":"1180","DOI":"10.1182\/blood-2014-09-598268","article-title":"Affinity of FVIII-specific antibodies reveals major differences between neutralizing and nonneutralizing antibodies in humans","volume":"125","author":"Hofbauer","year":"2015","journal-title":"Blood"},{"key":"10.1016\/j.jtha.2024.12.039_bib26","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1055\/s-0037-1615873","article-title":"CD4+ T cell response to factor VIII in hemophilia A, acquired hemophilia, and healthy subjects","volume":"82","author":"Reding","year":"1999","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.jtha.2024.12.039_bib27","doi-asserted-by":"crossref","first-page":"1842","DOI":"10.1182\/bloodadvances.2017008706","article-title":"CD4 T cells specific for factor VIII are present at high frequency in healthy donors and comprise na\u00efve and memory cells","volume":"1","author":"Meunier","year":"2017","journal-title":"Blood Adv"},{"key":"10.1016\/j.jtha.2024.12.039_bib28","doi-asserted-by":"crossref","first-page":"2159","DOI":"10.1046\/j.1538-7836.2003.00366.x","article-title":"Recognition of coagulation factor VIII by CD4+ T cells of healthy humans","volume":"1","author":"Hu","year":"2003","journal-title":"J\u00a0Thromb Haemost"},{"key":"10.1016\/j.jtha.2024.12.039_bib29","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1111\/j.1538-7836.2007.02336.x","article-title":"Depletion of CD4+\/CD25high regulatory T cells may enhance or uncover factor VIII-specific T-cell responses in healthy individuals","volume":"5","author":"Kamat\u00e9","year":"2007","journal-title":"J\u00a0Thromb Haemost"},{"key":"10.1016\/j.jtha.2024.12.039_bib30","doi-asserted-by":"crossref","first-page":"1791","DOI":"10.3324\/haematol.2019.230771","article-title":"International recommendations on the diagnosis and treatment of acquired hemophilia A","volume":"105","author":"Tiede","year":"2020","journal-title":"Haematologica"},{"key":"10.1016\/j.jtha.2024.12.039_bib31","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1182\/blood-2008-02-124941","article-title":"Dynamics of factor VIII interactions determine its immunologic fate in hemophilia A","volume":"112","author":"Lacroix-Desmazes","year":"2008","journal-title":"Blood"},{"key":"10.1016\/j.jtha.2024.12.039_bib32","doi-asserted-by":"crossref","first-page":"3739","DOI":"10.1182\/blood-2006-05-024711","article-title":"Polymorphisms in the TNFA gene and the risk of inhibitor development in patients with hemophilia A","volume":"108","author":"Astermark","year":"2006","journal-title":"Blood"},{"key":"10.1016\/j.jtha.2024.12.039_bib33","doi-asserted-by":"crossref","first-page":"3167","DOI":"10.1182\/blood-2005-09-3918","article-title":"Polymorphisms in the IL10 but not in the IL1beta and IL4 genes are associated with inhibitor development in patients with hemophilia A","volume":"107","author":"Astermark","year":"2006","journal-title":"Blood"},{"key":"10.1016\/j.jtha.2024.12.039_bib34","doi-asserted-by":"crossref","first-page":"2922","DOI":"10.1182\/blood-2011-09-379453","article-title":"F8 gene mutation type and inhibitor development in patients with severe hemophilia A: systematic review and meta-analysis","volume":"119","author":"Gouw","year":"2012","journal-title":"Blood"},{"key":"10.1016\/j.jtha.2024.12.039_bib35","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1055\/s-0038-1655945","article-title":"HLA genotype of patients with severe haemophilia A due to intron 22 inversion with and without inhibitors of factor VIII","volume":"77","author":"Oldenburg","year":"1997","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.jtha.2024.12.039_bib36","doi-asserted-by":"crossref","first-page":"826","DOI":"10.1055\/s-0037-1614124","article-title":"Characterization of antibodies induced by human factor VIII in a murine knockout model of hemophilia A","volume":"84","author":"Reipert","year":"2000","journal-title":"Thromb Haemost"},{"issue":"Suppl 2","key":"10.1016\/j.jtha.2024.12.039_bib37","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1046\/j.1351-8216.2001.00134.x","article-title":"Inhibitor development in correlation to factor VIII genotypes","volume":"8","author":"Oldenburg","year":"2002","journal-title":"Haemophilia"},{"key":"10.1016\/j.jtha.2024.12.039_bib38","doi-asserted-by":"crossref","first-page":"2054","DOI":"10.1056\/NEJMoa1516437","article-title":"A\u00a0randomized trial of factor VIII and neutralizing antibodies in hemophilia A","volume":"374","author":"Peyvandi","year":"2016","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jtha.2024.12.039_bib39","doi-asserted-by":"crossref","first-page":"236","DOI":"10.3324\/haematol.2018.206383","article-title":"Pathogenic immune response to therapeutic factor VIII: exacerbated response or failed induction of tolerance?","volume":"104","author":"Varthaman","year":"2019","journal-title":"Haematologica"},{"key":"10.1016\/j.jtha.2024.12.039_bib40","doi-asserted-by":"crossref","first-page":"6367","DOI":"10.1182\/blood-2010-09-308668","article-title":"United Kingdom Haemophilia Centre Doctors' Organisation (UKHCDO). Incidence of factor VIII inhibitors throughout life in severe hemophilia A in the United Kingdom","volume":"117","author":"Hay","year":"2011","journal-title":"Blood"},{"key":"10.1016\/j.jtha.2024.12.039_bib41","doi-asserted-by":"crossref","first-page":"1382","DOI":"10.1172\/JCI118558","article-title":"Neutralizing antiidiotypic antibodies to factor VIII inhibitors after desensitization in patients with hemophilia A","volume":"97","author":"Gilles","year":"1996","journal-title":"J\u00a0Clin Invest"},{"key":"10.1016\/j.jtha.2024.12.039_bib42","doi-asserted-by":"crossref","first-page":"1163","DOI":"10.1111\/j.1538-7836.2011.04267.x","article-title":"Successful immune tolerance induction by FVIII in hemophilia A patients with inhibitor may occur without deletion of FVIII-specific T cells","volume":"9","author":"Pautard","year":"2011","journal-title":"J\u00a0Thromb Haemost"},{"key":"10.1016\/j.jtha.2024.12.039_bib43","doi-asserted-by":"crossref","DOI":"10.1172\/JCI159925","article-title":"Immune tolerance against infused FVIII in hemophilia A is mediated by PD-L1+ Tregs","volume":"132","author":"Becker-Gotot","year":"2022","journal-title":"J\u00a0Clin Invest"},{"key":"10.1016\/j.jtha.2024.12.039_bib44","series-title":"Tending Adam's Garden","author":"Cohen","year":"2000"},{"key":"10.1016\/j.jtha.2024.12.039_bib45","doi-asserted-by":"crossref","first-page":"1130","DOI":"10.1126\/science.257.5073.1130","article-title":"Maintenance of in\u00a0vivo tolerance by persistence of antigen","volume":"257","author":"Ramsdell","year":"1992","journal-title":"Science"},{"key":"10.1016\/j.jtha.2024.12.039_bib46","doi-asserted-by":"crossref","first-page":"1355","DOI":"10.1182\/blood.2023021832","article-title":"Emicizumab prophylaxis in infants with hemophilia A (HAVEN 7): primary analysis of a phase 3b open-label trial","volume":"143","author":"Pipe","year":"2024","journal-title":"Blood"},{"key":"10.1016\/j.jtha.2024.12.039_bib47","doi-asserted-by":"crossref","first-page":"979","DOI":"10.1111\/hae.13848","article-title":"A\u00a0multicentre, open-label study of emicizumab given every 2 or 4 weeks in children with severe haemophilia A without inhibitors","volume":"25","author":"Shima","year":"2019","journal-title":"Haemophilia"},{"key":"10.1016\/j.jtha.2024.12.039_bib48","doi-asserted-by":"crossref","DOI":"10.3389\/fped.2022.992267","article-title":"Real-world experience of emicizumab prophylaxis in young children with hemophilia A: retrospective data from China","volume":"10","author":"Liu","year":"2022","journal-title":"Front Pediatr"},{"key":"10.1016\/j.jtha.2024.12.039_bib49","doi-asserted-by":"crossref","first-page":"e698","DOI":"10.1111\/hae.14432","article-title":"Real-world experience on the tolerability and safety of emicizumab prophylaxis in paediatric patients with severe haemophilia A with and without FVIII inhibitors","volume":"27","author":"Hassan","year":"2021","journal-title":"Haemophilia"},{"key":"10.1016\/j.jtha.2024.12.039_bib50","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1111\/hae.14318","article-title":"Emicizumab prophylaxis: prospective longitudinal real-world follow-up and monitoring","volume":"27","author":"Barg","year":"2021","journal-title":"Haemophilia"},{"key":"10.1016\/j.jtha.2024.12.039_bib51","doi-asserted-by":"crossref","first-page":"811","DOI":"10.1056\/NEJMoa1803550","article-title":"Emicizumab prophylaxis in patients who have hemophilia A without inhibitors","volume":"379","author":"Mahlangu","year":"2018","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jtha.2024.12.039_bib52","doi-asserted-by":"crossref","first-page":"e295","DOI":"10.1016\/S2352-3026(19)30054-7","article-title":"Efficacy, safety, and pharmacokinetics of emicizumab prophylaxis given every 4 weeks in people with haemophilia A (HAVEN 4): a multicentre, open-label, non-randomised phase 3 study","volume":"6","author":"Pipe","year":"2019","journal-title":"Lancet Haematol"},{"key":"10.1016\/j.jtha.2024.12.039_bib53","doi-asserted-by":"crossref","first-page":"e168","DOI":"10.1016\/S2352-3026(22)00377-5","article-title":"Emicizumab in people with moderate or mild haemophilia A (HAVEN 6): a multicentre, open-label, single-arm, phase 3 study","volume":"10","author":"N\u00e9grier","year":"2023","journal-title":"Lancet Haematol"},{"key":"10.1016\/j.jtha.2024.12.039_bib54","doi-asserted-by":"crossref","DOI":"10.1016\/j.rpth.2023.100278","article-title":"Factor VIII inhibitors in hemophilia A treated with emicizumab: longitudinal follow-up of outcomes","volume":"7","author":"Levy-Mendelovich","year":"2023","journal-title":"Res Pract Thromb Haemost"},{"key":"10.1016\/j.jtha.2024.12.039_bib55","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1080\/08880018.2021.2004269","article-title":"Breakthrough bleeding episodes in pediatric severe hemophilia a patients with and without inhibitors receiving emicizumab prophylaxis: a single-center retrospective review","volume":"39","author":"Hassan","year":"2022","journal-title":"Pediatr Hematol Oncol"},{"issue":"Suppl 3","key":"10.1016\/j.jtha.2024.12.039_bib56","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1111\/hae.14982","article-title":"Haemophilia in the era of novel therapies: where do inhibitors feature in the new landscape?","volume":"30","author":"Meeks","year":"2024","journal-title":"Haemophilia"},{"key":"10.1016\/j.jtha.2024.12.039_bib57","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1182\/blood.2019000658","article-title":"Timing of inhibitor development in more than 1000 previously untreated patients with severe hemophilia A","volume":"134","author":"van den Berg","year":"2019","journal-title":"Blood"},{"key":"10.1016\/j.jtha.2024.12.039_bib58","first-page":"1328","article-title":"Economic impact model of delayed inhibitor development in patients with hemophilia a receiving emicizumab for the prevention of bleeding events","volume":"22","author":"Patel","year":"2019","journal-title":"J\u00a0Med Econ"},{"key":"10.1016\/j.jtha.2024.12.039_bib59","doi-asserted-by":"crossref","first-page":"3203","DOI":"10.1111\/jth.15076","article-title":"The factor VIII treatment history of non-severe hemophilia A","volume":"18","author":"Abdi","year":"2020","journal-title":"J\u00a0Thromb Haemost"},{"key":"10.1016\/j.jtha.2024.12.039_bib60","doi-asserted-by":"crossref","first-page":"5785","DOI":"10.1182\/bloodadvances.2020002731","article-title":"The prospective Hemophilia Inhibitor PUP Study reveals distinct antibody signatures prior to FVIII inhibitor development","volume":"4","author":"Reipert","year":"2020","journal-title":"Blood Adv"},{"key":"10.1016\/j.jtha.2024.12.039_bib61","doi-asserted-by":"crossref","first-page":"1375","DOI":"10.1111\/bjh.19312","article-title":"Emicizumab prophylaxis in infants: Single-centre experience","volume":"204","author":"Levy-Mendelovich","year":"2024","journal-title":"Br J Haematol"},{"key":"10.1016\/j.jtha.2024.12.039_bib62","doi-asserted-by":"crossref","first-page":"1291","DOI":"10.1111\/hae.14847","article-title":"Dilemmas on emicizumab in children with haemophilia A: A survey of strategies from PedNet centres","volume":"29","author":"Ranta","year":"2023","journal-title":"Haemophilia"},{"key":"10.1016\/j.jtha.2024.12.039_bib63","doi-asserted-by":"crossref","first-page":"848","DOI":"10.1111\/hae.14959","article-title":"Emicizumab use in infancy: A survey of United States Pediatric Hemophilia Treatment Center Medical Directors","volume":"30","author":"Cohen","year":"2024","journal-title":"Haemophilia"},{"key":"10.1016\/j.jtha.2024.12.039_bib64","doi-asserted-by":"crossref","DOI":"10.11613\/BM.2017.030201","article-title":"Dealing with the positive publication bias: Why you should really publish your negative results","volume":"27","author":"Mlinari\u0107","year":"2017","journal-title":"Biochem Med (Zagreb)"},{"key":"10.1016\/j.jtha.2024.12.039_bib65","doi-asserted-by":"crossref","first-page":"505","DOI":"10.4103\/ija.IJA_142_19","article-title":"Publication bias - Importance of studies with negative results","volume":"63","author":"Nair","year":"2019","journal-title":"Indian J Anaesth"},{"key":"10.1016\/j.jtha.2024.12.039_bib67","doi-asserted-by":"crossref","DOI":"10.1016\/j.rpth.2024.102461","article-title":"Inhibitor development according to concentrate after 50 exposure days in severe hemophilia: data from the European HAemophilia Safety Surveillance (EUHASS)","volume":"8","author":"Fischer","year":"2024","journal-title":"Res Pract Thromb Haemost"},{"issue":"Suppl 1","key":"10.1016\/j.jtha.2024.12.039_bib68","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1080\/17474086.2023.2181781","article-title":"Building the foundation for a community-generated national research blueprint for inherited bleeding disorders: facilitating research through infrastructure, workforce, resources and funding","volume":"16","author":"Ragni","year":"2023","journal-title":"Expert Rev Hematol"},{"key":"10.1016\/j.jtha.2024.12.039_bib69","doi-asserted-by":"crossref","first-page":"809","DOI":"10.1111\/hae.14100","article-title":"Inhibitor development in previously untreated patients with severe haemophilia: A comparison of included patients and outcomes between a clinical study and a registry-based study","volume":"26","author":"Jonker","year":"2020","journal-title":"Haemophilia"}],"container-title":["Journal of Thrombosis and Haemostasis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1538783625000030?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1538783625000030?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,3,23]],"date-time":"2026-03-23T08:20:57Z","timestamp":1774254057000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1538783625000030"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4]]},"references-count":68,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2025,4]]}},"alternative-id":["S1538783625000030"],"URL":"https:\/\/doi.org\/10.1016\/j.jtha.2024.12.039","relation":{},"ISSN":["1538-7836"],"issn-type":[{"value":"1538-7836","type":"print"}],"subject":[],"published":{"date-parts":[[2025,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Tolerance to factor VIII in the era of nonfactor therapies: immunologic perspectives and a systematic review of the literature","name":"articletitle","label":"Article Title"},{"value":"Journal of Thrombosis and Haemostasis","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jtha.2024.12.039","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Published by Elsevier Inc. on behalf of International Society on Thrombosis and Haemostasis.","name":"copyright","label":"Copyright"}]}}